

## Technology Advisory Committee B Interests Register

Topic [ID3971]

Publication Date: 21/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Warren Linley	TAC Member	Direct financial	AstraZeneca is listed as a potential comparator company and he is currently engaged in a paid project with AstraZeneca in the area of mCRPC.	17/02/2023		It was agreed that his declaration would prevent Dr Linley from participating in discussions on this appraisal.
Stephen Allen	Patient expert	Financial	His nominating organisation, Tackle Prostate Cancer, have received income from the pharmaceutical industry.	09/03/2023		It was agreed that his declaration would not prevent Stephen from providing expert advice to the committee.
Amit Bahl	Clinical expert	Professional and financial interests	He has received meeting support and honoraria payments for educational meetings and advisory boards from Bayer, Astellas, Janssen, Novartis, EUSA, BMS, Pfizer and AAA. He also declared research grants to Institution	12/09/2022 09/03/2023		It was agreed that his declaration would not prevent Amit from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			from Sanofi, Janssen and Bayer.			
Dr Simon Hughes	Clinical expert	Professional and financial	Guy's Cancer Academy (for which he is the lead) received an unrestricted grant from Bayer PLC to develop an open access online e-learning course (CPD accredited) on the management of non-metastatic Castration Resistant Prostate Cancer (Bayer had no input regarding the content); He chaired an Advisory Board for Bayer PLC concerning the ARASENS trial and received an honorarium for this; He is a mentor on the Bayer "Future Leaders in Oncology" programme for which he receives an honorarium; He co-Chairs and co-organises the Annual PROSPECT meeting (a UK multidisciplinary prostate	12/09/2022		It was agreed that his declaration would not prevent Dr Hughes from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>cancer meeting funded by Astellas) for which he receives an honorarium; He has also received honoraria from Astellas for delivering a webinar to Astellas Europe staff on managing the side effects of androgen deprivation and delivering a series of webinars on the management of bone health in patients on androgen deprivation; Guy's Cancer Academy received an unrestricted grant from Astellas to develop a credit bearing course (at Kings College London) on prostate cancer for advanced non-medical practitioners; Guy's Cancer Academy have just signed a contract with Janssen Brazil to run a 2-day preceptorship for visiting</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			oncologists from Brazil to cover the whole spectrum of prostate cancer management (and are also exploring a similar model with their European team); He receives honoraria from AstraZeneca to advise on their PARP inhibitor research programme, and their clinician education programme around PARPi.			
Peter Wheatley-Price	TAC Member	Financial	His employer, Takeda, manufacture Leuprorelin (Prostap), an LHRH agonist used in hormone sensitive stages of prostate cancer.	17/02/2023		It was agreed that his declaration would not prevent Peter from participating in discussions on this appraisal.

### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.